Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115

Catalyst Pharmaceutical Partners, Inc. CPRX today announced that the European Commission has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (EMA) Committee on Orphan Medicinal Products after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment.